Mehmet Akce
University of Alabama at Birmingham · Sponsor-Investigator · The University of Alabama at Birmingham
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mehmet Akce as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06855225 · A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaMehmet Akce · not yet recruiting · Combined Hepatocellular and Cholangiocarcinoma · principal investigator
- Ph2NCT06728410 · A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce · recruiting · Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation · principal investigator
- Ph1/Ph2NCT06294548 · A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCCUniversity of Alabama at Birmingham · recruiting · Hepatocellular Carcinoma · principal investigator
- Ph1NCT06182072 · ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)ProDa BioTech, LLC · recruiting · Pancreatic Ductal Adenocarcinoma (PDAC) · principal investigator
- Ph2NCT05199285 · A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabAcademic and Community Cancer Research United · terminated · BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma · principal investigator
- Ph2NCT05194293 · Regorafenib and Durvalumab for the Treatment of High-Risk Liver CancerAcademic and Community Cancer Research United · active not recruiting · Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026Named on NCT05199285, NCT05194293
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:15 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma.Ann Surg Oncol · 202379 citationsRCR 7.8
- Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.J Immunother Cancer · 202349 citationsRCR 3.8
- Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine.Cell Rep Med · 202525 citationsRCR 5.8
- Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.Cancer Chemother Pharmacol · 202116 citationsRCR 1.0
- A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.Clin Cancer Res · 202013 citationsRCR 0.5
- 12 citationsRCR 0.7
- Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.Invest New Drugs · 201910 citationsRCR 0.3
- Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma.Oncologist · 20252 citationsRCR 0.4
- Provider Recommendations for Phase I Clinical Trials Within a Shared Decision-Making Model in Phase I Cancer Clinical Trial Discussions.JCO Oncol Pract · 20201 citationsRCR 0.1